Jackie Miller Provides an Overview of Virtua's Camp Oasis

Commentary
Article

Jackie Miller, RN, BSN, OCN, nurse navigator, Virtua Fox Chase Cancer Program, provides an overview of a day of fun, support and education for children and teens who have a loved one with cancer.

Jackie Miller, RN, BSN, OCN, nurse navigator, Virtua Fox Chase Cancer Program, provides an overview of a day of fun, support and education for children and teens who have a loved one with cancer.

Learn more about the program here.

Recent Videos
Anne M. Reb, PhD, NP, discussing a nurse-led intervention for fear of cancer recurrence.
Ann H. Partridge, MD, MPH, in an interview with Oncology Nursing News at 2024 ESMO Congress.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Related Content
RX Road Map: Glofitamab-gxbm (Columvi)

RX Road Map: Glofitamab-gxbm (Columvi)

Jennie Gilliland, MSN, RN, OCN;Caitlin Fanning, MSN, RN, OCN
September 26th 2024
Article
Thirteen at Fox Chase Cancer Center Honored as 2024 Top Nurses by Main Line Today

Thirteen at Fox Chase Cancer Center Honored as 2024 Top Nurses by Main Line Today

Fox Chase Cancer Center
May 15th 2024
Article
We Advance, Together

We Advance, Together

Fox Chase Cancer Center
February 29th 2024
Article
Fox Chase Cancer Center Nurse Navigators Improve Patient Services While Also Increasing Patient and Nurse Satisfaction

Fox Chase Cancer Center Nurse Navigators Improve Patient Services While Also Increasing Patient and Nurse Satisfaction

Fox Chase Cancer Center
July 30th 2023
Article
lung cancer

Innovative Patient Education Strategies Continue to be Developed for Lung Cancer Screening

Kyle Doherty
June 12th 2023
Article

Novel strategies for patient education can help to build trust in and decrease the fear of lung cancer screening among patients.

Patients With uHCC Who Experience irAEs With Tremelimumab/Durvalumab Achieve Numerical Improvements in OS

Patients With uHCC Who Experience irAEs With Tremelimumab/Durvalumab Achieve Numerical Improvements in OS

Lindsay Fischer
June 3rd 2023
Article

Tremelimumab plus durvalumab (STRIDE) showed a manageable immune-related adverse event profile in the phase 3 HIMALAYA trial.

© 2024 MJH Life Sciences

All rights reserved.